ReviewFrontiers in oncology2021

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.

Andriy Krendyukov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.